Original language | English (US) |
---|---|
Pages (from-to) | 761-763 |
Number of pages | 3 |
Journal | Hepatology |
Volume | 75 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
ASJC Scopus subject areas
- Hepatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Reply. / Ghany, Marc G.; King, Wendy C.; Lisker-Melman, Mauricio et al.
In: Hepatology, Vol. 75, No. 3, 03.2022, p. 761-763.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
AU - Ghany, Marc G.
AU - King, Wendy C.
AU - Lisker-Melman, Mauricio
AU - Lok, Anna S.F.
AU - Terrault, Norah
AU - Janssen, Harry L.A.
AU - Khalili, Mandana
AU - Chung, Raymond T.
AU - Lee, William M.
AU - Lau, Daryl T.Y.
AU - Cloherty, Gavin A.
AU - Sterling, Richard K.
N1 - Funding Information: The authors acknowledge the use of Hepatitis B Research Network (HBRN) samples and data as the sole contribution of the HBRN. The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01-DK082843), Anna Suk-Fong Lok, MD (U01-DK082863), Steven H. Belle, PhD, MScHyg (U01-DK082864), Kyong-Mi Chang, MD (U01-DK082866), Michael W. Fried, MD (U01-DK082867), Adrian M. Di Bisceglie, MD (U01-DK082871), William M. Lee, MD (U01-DK082872), Harry L. A. Janssen, MD, PhD (U01-DK082874), Daryl T-Y Lau, MD, MPH (U01-DK082919), Richard K. Sterling, MD, MSc (U01-DK082923), Steven-Huy B. Han, MD (U01-DK082927), Robert C. Carithers, MD (U01-DK082943), and Mandana Khalili, MD (U01-DK082944); an interagency agreement with NIDDK: Lilia M. Ganova-Raeva, PhD (A-DK-3002-001); and support from the intramural program, NIDDK, National Institues of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong-Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01-RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, National Center for Advancing Translational Sciences, NIH), Mandana Khalili, MD, MAS (CTSA UL1TR000004), Michael W. Fried, MD (CTSA UL1TR001111), and Anna Suk-Fong Lok (CTSA UL1RR024986 and U54TR001959.) Additional support was provided by Gilead Sciences, Inc., and Roche Molecular Systems via a CRADA through the NIDDK. Funding Information: Dr. Lau consults for Abbott and advises Gilead. Dr. King received grants from AbbVie. Dr. Lisker‐Melman is on the speakers’ bureau for AbbVie and Gilead. Dr. Terrault consults for EXIGO, ENYO, PPD Pharma, and Entourage. She received grants from Gilead, Genentech, and Roche. Dr. Janssen consults and received grants from Gilead, GlaxoSmithKline, Janssen, Roche, and Vir. He consults for Aligos, Antios, Arbutus, Eiger, Viroclinics, and VBI Vaccines. He received grants from AbbVie. Dr. Khalili consults and received grants from Gilead. She received grants from AbbVie. Dr. Chung received grants from Gilead, Bristol‐Myers Squibb, Boehringer Ingelheim, Janssen, Merck, and Roche. Dr. Lee consults for Forma, SeaGen, Karuna, and Cortexyme. He received grants from Merck, Bristol‐Myers Squibb, Intercept, Aurora, Novo Nordisk, Cumberland, and Meridian. Dr. Cloherty is employed and owns stock in Abbott. Dr. Sterling is on the data security monitoring board for AskBio and Pfizer. He received grants from Roche, Abbott, AbbVie, and Gilead. Funding Information: The authors acknowledge the use of Hepatitis B Research Network (HBRN) samples and data as the sole contribution of the HBRN. The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01‐DK082843), Anna Suk‐Fong Lok, MD (U01‐DK082863), Steven H. Belle, PhD, MScHyg (U01‐DK082864), Kyong‐Mi Chang, MD (U01‐DK082866), Michael W. Fried, MD (U01‐DK082867), Adrian M. Di Bisceglie, MD (U01‐DK082871), William M. Lee, MD (U01‐DK082872), Harry L. A. Janssen, MD, PhD (U01‐DK082874), Daryl T‐Y Lau, MD, MPH (U01‐DK082919), Richard K. Sterling, MD, MSc (U01‐DK082923), Steven‐Huy B. Han, MD (U01‐DK082927), Robert C. Carithers, MD (U01‐DK082943), and Mandana Khalili, MD (U01‐DK082944); an interagency agreement with NIDDK: Lilia M. Ganova‐Raeva, PhD (A‐DK‐3002‐001); and support from the intramural program, NIDDK, National Institues of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong‐Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01‐RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, National Center for Advancing Translational Sciences, NIH), Mandana Khalili, MD, MAS (CTSA UL1TR000004), Michael W. Fried, MD (CTSA UL1TR001111), and Anna Suk‐Fong Lok (CTSA UL1RR024986 and U54TR001959.) Additional support was provided by Gilead Sciences, Inc., and Roche Molecular Systems via a CRADA through the NIDDK.
PY - 2022/3
Y1 - 2022/3
UR - http://www.scopus.com/inward/record.url?scp=85121444001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121444001&partnerID=8YFLogxK
U2 - 10.1002/hep.32251
DO - 10.1002/hep.32251
M3 - Letter
C2 - 34800047
AN - SCOPUS:85121444001
VL - 75
SP - 761
EP - 763
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 3
ER -